Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India

Bristol-Myers SquibbThe Bristol-Myers Squibb Foundation today announced the expansion of its Together on Diabetes® initiative to China and India, pledging $15 million over five years to help these developing nations with rapidly growing numbers of type 2 diabetes patients.

The International Diabetes Foundation (IDF) reports that more than 90 million people in China - 9.3 percent of the population - had type 2 diabetes in 2011, the most of any country. That figure is projected to grow to 129.7 million, or 12.1 percent of the population, by 2030.

India, which has 61.26 million people diagnosed with type 2 diabetes (8.3 percent of the population), ranks second only to China in total cases and third behind the United States (10.9 percent) and China in terms of prevalence. By 2030, India will have 101.2 million people with type 2 diabetes, IDF projects.

"In keeping with a long legacy of addressing global health issues through innovative and sustainable philanthropic programs, Bristol-Myers Squibb and the Bristol-Myers Squibb Foundation are pleased to expand our philanthropic work in type 2 diabetes to China and India, where the disease has become a significant public health concern," said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. "We look forward to working with the Shanghai Charity Foundation to improve the management of type 2 diabetes in Shanghai."

As part of today's announcement, Together on Diabetes® awarded the Shanghai Charity Foundation (SCF) a grant of US $522,797 over three years to create an efficient and effective community-based, block-by-block approach for managing type 2 diabetes in Shanghai, a mega-city of 23 million people.

The most recent survey conducted by the Shanghai Center for Disease Control (SCDC) shows the prevalence of type 2 diabetes in Shanghai reached 16 percent last year, more than 6 percentage points above the national average and nearly 5 percentage points higher than other Chinese cities.

Working with the SCDC and the Shanghai Municipal Health Bureau, SCF will leverage existing city management systems and technology to build and pilot an integrated model of diabetes prevention and management that can be deployed in other Chinese cities.

"As their populations grow older and more sedentary, health authorities in China and India are seeing many of the same problems experienced by their Western counterparts, namely obesity and type 2 diabetes," said John Damonti, president, Bristol-Myers Squibb Foundation and vice president, Corporate Philanthropy, Bristol-Myers Squibb. "What's worse, we are seeing only the tip of the iceberg. For every patient in China or India who has been diagnosed with type 2 diabetes, there are several others who are undiagnosed or considered pre-diabetic. That is why Bristol-Myers Squibb and its Foundation are introducing to China and India the Together on Diabetes® model developed in the United States and working with prestigious partners in both countries to address this growing public health issue."

The additional $15 million commitment for Together on Diabetes® builds upon more than a decade of work by the Foundation and its partners in China to reduce health disparities and fight serious diseases by strengthening community-based health care worker capacity and integrating medical care and community-based supportive services. The first Together on Diabetes® grants in India and additional grants in China will be announced later.

Bristol-Myers Squibb is celebrating three milestones in 2012: the 125th anniversary of the company's founding; the 30th anniversary of the establishment of the company's joint venture in China, Sino-American Shanghai Squibb Pharmaceuticals Ltd.; and the 10th anniversary of the Foundation's Delivering Hope® initiative to address hepatitis B and C in Asia.

Delivering Hope® has donated more than US $4.5 million to 16 projects on mainland China and three in Taiwan. More than 8 million people in China who are at high risk of hepatitis infection have benefitted from Delivering Hope® programs over the past decade.

About Together on Diabetes®
Together on Diabetes® is a 5 year, $115 million philanthropic initiative of the Bristol-Myers Squibb Foundation to improve health outcomes of people living with type 2 diabetes in the United States, China and India by strengthening patient self-management education, community-based supportive services and broad-based community mobilization. Consistent with the Bristol-Myers Squibb Foundation's mission to reduce health disparities, the initiative targets populations disproportionately affected by type 2 diabetes.

About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes for patients around the world who are disproportionately affected by serious disease.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...